Probiotics

Disease-a-Month

Volumn 61, Issue 7, 2015, Pages 259-290

  Mizock, Barry A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOSTRIDIUM PROBIOTIC AGENT; ENGINEERED PROBIOTIC AGENT; MICROENCAPSULATED PROBIOTIC AGENT; PREBIOTIC AGENT; PROBIOTIC AGENT; SECRETORY IMMUNOGLOBULIN; SYNBIOTIC AGENT; UNCLASSIFIED DRUG;

ACUTE DIARRHEA; ALLERGIC DISEASE; ANTIBIOTIC ASSOCIATED DIARRHEA; ANTIMICROBIAL ACTIVITY; ATHEROSCLEROSIS; BACTERIAL COLONIZATION; BACTERIUM CULTURE; BINDING SITE; BIOENGINEERING; CHILDHOOD DISEASE; COLORECTAL CANCER; COMMENSAL; CRITICAL ILLNESS; CROHN DISEASE; DIABETES MELLITUS; DIARRHEA; DRUG SAFETY; DYSBIOSIS; ECOLOGY; FOOD; HEALTH; HUMAN; ILEITIS; IMMUNOGLOBULIN PRODUCTION; INFECTIOUS DIARRHEA; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; IRRITABLE COLON; LIFESPAN; MAINTENANCE THERAPY; METAGENOME; METAGENOMICS; MICROBIOME; MICROENCAPSULATION; MICROFLORA; MICROORGANISM; NONALCOHOLIC FATTY LIVER; NUTRITIONAL REQUIREMENT; OBESITY; PRACTICE GUIDELINE; PRIMARY PREVENTION; RADIATION ENTEROPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SECONDARY PREVENTION; TRAVELLER DIARRHEA; ULCERATIVE COLITIS; VAGINA CANDIDIASIS; VAGINITIS; COLORECTAL TUMOR; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TRACT; INFLAMMATORY BOWEL DISEASES; INTESTINE; IRRITABLE BOWEL SYNDROME; MICROBIOLOGY; POUCHITIS; TRAVEL; VAGINOSIS, BACTERIAL;

COLORECTAL NEOPLASMS; DYSBIOSIS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINES; IRRITABLE BOWEL SYNDROME; MICROBIOTA; POUCHITIS; PRIMARY PREVENTION; PROBIOTICS; REMISSION INDUCTION; SECONDARY PREVENTION; TRAVEL; VAGINOSIS, BACTERIAL;

EID: 84930540029     PISSN: 00115029     EISSN: 15578194     Source Type: Journal    
DOI: 10.1016/j.disamonth.2015.03.011     Document Type: Review

References (147)

1. Dominguez-Bello M.G., Blaser M.J., Ley R.E., et al. Development of the human gastrointestinal microbiota and insights from high-throughput sequencing. Gastroenterology 2011, 140:1713-1719.
2. Fouhy F., Guinane C.M., Hussey S., et al. High-throughput sequencing reveals the incomplete, short-term recovery of infant gut microbiota following parenteral antibiotic treatment with ampicillin and gentamicin. Antimicrob Agents Chemother 2012, 56:5811-5820.
3. Claesson M.J., Jeffery I.B., Conde S., et al. Gut microbiota composition correlates with diet and health in the elderly. Nature 2012, 488:178-184.
4. Suau A., Bonnet R., Sutren M., et al. Direct analysis of genes encoding 16S rRNA from complex communities reveals many novel molecular species within the human gut. Appl Environ Microbiol 1999, 65:4799-4807.
5. Uchiyanma T., Miyazaki K. Functional metagenomics for enzyme discovery: challenges to efficient screening. Curr Opin Biotechnol 2009, 20:616-622.
6. Arumagam M., Raes J., Pelletier E., et al. Enterotypes of the human gut microbiome. Nature 2011, 473:174-180.
7. Wu G.D., Chen J., Hoffmann C., et al. Linking long-term dietary patterns with gut microbial enterotypes. Science 2011, 334:105-108.
8. Jeffery I.B., Claesson M.J., O'Toole P.W. Categorization of the gut microbiota: enterotypes or gradients?. Nat Rev 2012, 10:591-592.
9. Caporaso J.G., Lauber C.L., Costello E.K., et al. Moving pictures of the human microbiome. Genome Biol 2011, 12:R50.
10. Ursell L.K., Haiser H.J., Van Truen W., et al. The intestinal metabolome: an intersection between microbiota and host. Gastroenterology 2014, 146:1470-1476.
11. De Vuyst L., Leroy F. Cross-feeding between bifidobacteria and butyrate-producing colon bacteria explains bifidobacterial competitiveness, butyrate production, and gas production. Int J Food Microbiol 2011, 149:73-80.
12. Pryde S.E., Duncan S.H., Hold G.L. The microbiology of butyrate formation in the human colon. FEMS Microbiol Lett 2002, 217:133-139.
13. Macfarlane G.T., Macfarlane S., Blackett K.L. Fermentation and the effects of probiotics on host metabolism. Probiotics: A Clinical Guide 2010, 83-94. Slack Incorporated, Thorofare, NJ. M.H. Floch, A.S. Kim (Eds.).
14. Steinhart A.H., Hiruki T., Brzezinski A., et al. Treatment of left-sided ulcerative colitis with butyrate enemas: a controlled trial. Aliment Pharmacol Ther 1996, 10:729-736.
15. Cani P.D., Delzenne N.M. The role of gut microbiota in energy metabolism and metabolic disease. Curr Pharm Des 2009, 15:1546-1558.
16. Ley R.E., Turnbaugh P.J., Klein S., et al. Microbial ecology: human gut microbes associated with obesity. Nature 2006, 444:1022-1023.
17. Turnbaugh P.J., Ridaura V.K., Faith J.J., et al. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med 2009, 1:6ra14.
18. Hildebrandt M.A., Hoffmann C., Sherrill-Mix S.A., et al. High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology 2009, 137:1716-1724.
19. Ghosh S., DeCoffe D., Brown K., et al. Fish oil attenuates omega-6 polyunsaturated fatty acid-induced dysbiosis and infectious colitis but impairs LPS dephosphorylation activity causing sepsis. PLoS One 2013, 8:e55468.
20. Cani P.D., Amar J., Iglesias M.A., et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007, 56:1761-1772.
21. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 2006, 444:860-867.
22. Mekkes M.C., Weenen T.C., Brummer R.J., et al. The development of probiotic treatment in obesity: a review. Benef Microbes 2014, 5:19-28.
23. Sherman P.M., Ossa J.C., Johnson-Henry K. Unraveling mechanisms of action of probiotics. Nutr Clin Pract 2009, 10:10-14.
24. Asad S., Opal S.M. Bench-to-bedside review: quorum sensing and the role of cell-to-cell communication during invasive bacterial infection. Crit Care 2008, 12:236.
25. Vanderhoof J.A., Whitney D.B., Antonson D.L., et al. Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children. J Pediatr 1999, 135:564-568.
26. Kotowska M., Albrecht P., Szajewska H. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea in children: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 2005, 21:583-590.
27. Johnston B.C., Goldenberg J.Z., Vandvik P.O., et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev 2011, 5. CD004827, 10.1002/14651858.CD006095.pub3.
28. Gao X.W., Mubasher M., Fang C.Y., et al. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL 1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol 2010, 105:1636-1641.
29. Ojetti V., Bruno G., Ainora M.E., et al. Impact of Lactobacillus reuteri supplementation on anti-Helicobacter pylori levofloxacin-based second-line therapy. Gastroenterol Res Pract 2012, 740381.
30. Armuzzi A., Cremonini F., Bartolozzi F., et al. The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2001, 15:163-169.
31. Goldenberg J.Z., Ma S.S.Y., Saxton J.D., et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Sys Rev 2013, 5:CD006095. 10.1002/14651858.CD006095.pub3.
32. Pillai A., Nelson R. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev 2008, 1:CD004611. 10.1002/14651858.CD004611.pub2.
33. McFarland L.V., Surawicz C.M., Greenberg R.N., et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. J Am Med Assoc 1994, 271:1913-1918.
34. Floch M.H. Recommendations for probiotic use in humans-a 2014 update. Pharmaceuticals (Basel) 2014, 7:999-1007.
35. Thomas D.W., Freer F.R. Committee on nutrition, section on gastroenterology, hepatology, and nutrition. Pediatrics 2010, 126:1217-1231.
36. McFarland L.V. Meta-analysis of probiotics for the prevention of traveler's diarrhea. Travel Med Infect Dis 2007, 5:97-105.35.
37. Takahashi O., Noguchi Y., Omata F., et al. Probiotics in the prevention of traveler's diarrhea. Meta-analysis (letter). J Clin Gastroenterol 2007, 41:336-337.
38. Allen S.J., Martinez E.G., Gregorio G.V., et al. Probiotics for treating acute infectious diarrhea. Cochrane Database Syst Rev 2010, 11:CD003048. 10.1002/14651858.CD003048.pub3.
39. Szajewska H., Skorka A., Ruszczynski, et al. Meta-analysis: Lactobacillus GG for treating acute gastroenteritis in children-updated analysis of randomised controlled trials. Aliment Pharmacol Ther 2013, 38:467-476.
40. Klement E. Cohen R.V. Boxman J. et al. Breastfeeding and risk of inflammatory bowel disease: a systematic review with meta-analysis. Am J Clin Nutr 2004 80:1342-1352.
41. Chow J. Mazmanian S.K. A pathobiont of the microbiota balances host colonization and intestinal inflammation. Cell Host Microbe 2010 7:265-276.
42. Sartor R.B. Mazmanian S.K. Intestinal microbes in inflammatory bowel diseases. Am J Gastroenterol Suppl 2012 1:15-21.
43. Morgan X.C. Tickle T.I. Sokol H. et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol 2012 13:R79.
44. Sood A. Midha V. Makharia G.K. et al. The probiotic preparation VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2009 7:1202-1209.
45. Tursi A. Brandimarte G. Papa A. et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind randomized placebo-controlled study. Am J Gastroenterol 2010 105:2218-2227.
46. Bibiloni R. Fedorak R.N. Tannock G.W. et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005 100:1539-1546.
47. Miele E. Pascarella F. Giannetti E. et al. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 2009 104:437-443.
48. Kruis W. Fric P. Pokrotnieks J. et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004 53:1617-1623.
49. Shen J. Zuo Z.X. Maa A.P. Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis Crohn's disease and pouchitis: meta-analysis of randomized controlled trials. Inflamm Bowel Dis 2014 20:21-35.
50. Fujiya M. Ueno N. Kohgo Y. Probiotic treatments for induction and maintenance of remission in inflammatory bowel diseases: a meta-analysis of randomized controlled trials. Clin J Gastroenterol 2014 7:1-13.
51. Mardini H.E. Grigorian A.Y. Probiotic mix VSL#3 is effective adjunctive therapy for mild to moderately active ulcerative colitis: a meta-analysis. Inflamm Bowel Dis 2014 20:1562-1567.
52. Naidoo K. Gordon M. Fagbemi A.O. et al. Probiotics for maintenance of remission in ulcerative colitis. Cochrane Database Sys Rev 2011 12:CD007443. 10.1002/14651858.CD007443.pub2.
53. Ruseler-van Embden J.G.H. Schouten W.R. van Lieshout L.M.C. Pouchitis: result of microbial imbalance?. Gut 1994 35:658-664.
54. Gionchetti P. Rizzello F. Venturi A. et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind placebo-controlled trial. Gastroenterology 2000 119:305-309.
55. Giochetti P. Rizzello F. Helvig U. et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind placebo controlled trial. Gastroenterology 2003 124:1202-1209.
56. Gionchetti P. Rizzello F. Morselli C. et al. High-dose probiotics for the treatment of active pouchitis. Dis Colon Rectum 2007 50:2075-2082.
57. Mimura T. Rizzello F. Helwig U. et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004 53:108-114.
58. Shen B. Brzezinski A. Fazio V.W. et al. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice. Aliment Pharmacol Ther 2005 22:721-728.
59. Elahi B. Nikfar S. Derakhshani S. et al. On the benefit of probiotics in the management of pouchitis in patients underwent ileal pouch anal anastomosis: a meta-analysis of controlled clinical trials. Dig Dis Sci 2008 53:1278-1284.
60. Rolfe V.E. Fortun P.J. Hawkey C.J. et al. Probiotics for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2006 4:CD004826.
61. Butterworth A.D. Thomas A.G. Akobeng A.K. Probiotics for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2008 3:CD006634. http://dx.doi.org/10.1002/14651858.CD006634.pub2.
62. Prantera C. Scribano M.L. Falasco G. et al. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 2002 51:405-409.
63. Marteau P. Lemann M. Seksik P. et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised double blind placebo controlled GETAID trial. Gut 2006 55:842-847.
64. Van Gossum A. Dewit O. Louis E. et al. Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii LA1) on early endoscopic recurrence of Crohn's diseases after ileo-caecal resection. Inflamm Bowel Dis 2007 13:135-142.
65. Ghouri Y.A. Richards D.M. Rahimi E.F. et al. Systematic review of randomized controlled trials of probiotics prebiotics and synbiotics in inflammatory bowel disease. Clin Exp Gastroenterol 2014 7:473-487.
66. Guarner F. Khan A.G. Garisch J. et al. World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics October 2011. J Clin Gastroenterol 2012 46:468-481.
67. Porter C.K. Gormley R. Tribble D.R. The incidence and gastrointestinal infectious risk of function gastrointestinal disorders in a healthy US adult population. Am J Gastroenterol 2011 106:130-138.
68. Salonen A. de Vos W.M. Palva A. Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives. Microbiology 2010 156:3205-3215.
69. Xu G.Y. Winston J.H. Shenoy M. et al. The endogenous hydrogen sulfide producing enzyme cystathionine-beta synthase contributes to visceral hypersensitivity in a rat model of irritable bowel syndrome. Mol Pain 2009 5:44.
70. Spiller R. Review article: probiotics and prebiotics in irritable bowel syndrome. Aliment Pharmacol Ther 2008 28:385-396.
71. Moayyedi P. Ford A.C. Talley N.J. et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 2010 59:325-332.
72. Brenner D.M. Moeller M.J. Chey W.D. et al. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol 2009 104:1033-1049.
73. Ford A.C. Moayyedi P. Lacy B.E. et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol 2014 109:S2-S26.
74. Maliol J. Crane J. von Mutius E. et al. The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three: a global synthesis. Allergol Immunopathol (Madr) 2013 41:73-85.
75. Strachan D.P. Hay fever hygiene and household size. Br Med J 1989 299:1259-1260.
76. Brooks C. Pearce N. Douwes J. The hygiene hypothesis in allergy and asthma: an update. Curr Opin Allergy Clin Immunol 2013 13:70-77.
77. Kalliomake M. Kirjavainen P. Eerola E. et al. Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not developing. J Allergy Clin Immunol 2001 107:129-134.
78. Flohr C. Nagel G. Weinmayr G. et al. Lack of evidence for a protective effect of prolonged breastfeeding on childhood eczema: lessons from the International Study of Asthma and Allergies in Childhood (ISAAC) Phase Two. Br J Dermatol 2011 165:1280-1289.
79. Dogaru C.M. Strippoli M.F.P. Spycher B.D. et al. Breastfeeding and lung function at school age. Am J Respir Crit Care Med 2012 185:874-880.
80. Kalliomaki M. Salminen S. Arvilommi H. et al. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 2001 357:1076-1079.
81. Kopp M. Hennemuth I. Heinzmann A. et al. Randomized double-blind placebo-controlled trial of probiotics for primary prevention: no clinical effects of Lactobacillus GG supplementation. Pediatrics 2008 121:e850-e856.
82. Tang M.L.K. Lahtinen S.J. Boyle R.J. Probiotics and prebiotics: clinical effects in allergic disease. Curr Opin Pediatr 2010 22:626-634.
83. Abrahamsson T. Olofsson M. Ludvigsson J. et al. Can postnatal supplementation with probiotics reduce the risk for allergic disease in infancy?. Pediatr Res 2010 68:48-49.
84. Panduru M. Panduru N.M. Salavastru C.M. et al. Probiotics and primary prevention of a topic dermatitis: a meta-analysis of randomized controlled studies. J Eur Acad Dermatol Venereol 2015 29:232-242.
85. Foolad N. Brezinski E.A. Chase E.P. et al. Effect of nutrient supplementation on atopic dermatitis in children. JAMA Dermatol 2013 149:350-355.
86. Osborn D.A. Sinn J.K. Probiotics in infants for prevention of allergic disease and food hypersensitivity. Cochrane Database Syst Rev 2007 4:CD006475.
87. Osborn D.A. Sinn J.K. Prebiotic in infants for prevention of allergic disease and food hypersensitivity. Cochrane Database Syst Rev 2007 3:CD006474. 10.1002/14651858.CD006634.pub2.
88. Majamaa H. Isolauri E. Probioics: a novel approach in the management of food allergy. J Allergy Clin Immunol 1997 99:179-185.
89. Boyle R.J. Bath-Hextall F.J. Leonardi-Bee J. et al. Probiotics for treating eczema. Cochrane Database Syst Rev 2008 4:CD006135. 10.1002/14651858.CD006135.pub2.
90. Wang Z. Klipfell E. Bennett B.J. et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011 472:57-63.
91. Martin F.P.J. Wang Y. Sprenger N. et al. Probiotic modulation of symbiotic gut microbial-host metabolic interactions in a humanized microbiome mouse model. Mol Syst Biol 2008 4:1-15.
92. Jones M.L. Martoni C.J. Parent M. et al. Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults. Br J Nutr 2012 107:1505-1513.
93. Jones M.L. Martoni C.J. Prakash S. Cholesterol lowering and inhibition of sterol absorption by Lactobacillus reuteri NCIMB 30242: a randomized controlled trial. Eur J Clin Nutr 2012 66:1234-1241.
94. DiRienzo D.B. Effect of probiotics on biomarkers of cardiovascular disease: implications for heart-healthy diets. Nutr Rev 2014 72:18-29.
95. Sobel J. Management of recurrent vulvovaginal candidiasis: unresolved issues. Curr Infect Dis Rep 2006 8:481-486.
96. Anukam K. Osazuwa E. Ahonkhai I. et al. Augmentation of antimicrobial metronidazole theray of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized double-blind placebo controlled trial. Microbes Infect 2006 8:1450-1454.
97. Ehrstrom S. Daroczy K. Rylander e. et al. Lactic acid bacteria colonization and clinical outcome after probiotic supplementation in conventionally treated bacterial vaginosis and vulvovaginal candidiasis. Microbes Infect 2010 12:691-699.
98. Hilton E. Isenberg H.D. Alperstein P. et al. Ingestion of yogurt containing Lactobacillus acidophilus as prophylaxis for candida vaginitis. Ann Intern Med 1992 116:353-357.
99. Hay P. Patel S. Daniels D. British Association for Sexual Health and HIV 2012 1-15. U.K. Clinical Effectiveness Group British Association for Sexual Health and HIV (BASHH) London (UK).
100. Sobhani I. Amiot A. Le Baleur Y. et al. Microbial dysbiosis and colon carcinogenesis: could colon cancer be considered a bacteria-related disease?. Therap Adv Gastroenterol 2013 6:215-229.
101. Wang T. Cai G. Qui Y. et al. Structural segregation of gut microbiota between colorectal cancer patients and health volunteers. ISME J 2012 6:320-329.
102. Tjalsma H. Boleij A. Marchesi J. et al. A bacterial driver-passenger model for colorectal cancer: beyond the usual suspects. Nat Rev Microbiol 2012 10:575-582.
103. Schulz M.D. Atay C. Heringer J. et al. Higih-fat-diet mediated dysbiosis promotes intestinal carcinogenesis independently of obesity (letter). Nature 2014 514:508-512.
104. Uccello M. Malaguarnera G. Basile F. et al. Potential role of probiotics on colorectal cancer prevention. BMC Surgery 2012 12(suppl 1):S35.
105. Iyer C. Kosters A. Sethi G. et al. Probiotic Lactobacillus reuteri promotes TNF induced apoptosis in human myeloid leukemia-derived cells by modulation of NFΚand MAPK signaling. Cellular Microbiol 2008 10:1442-1452.
106. Serban D.E. Gastrointestinal cancers: influence of gut microbiota probiotics and prebiotics. Cancer Lett 2014 345:258-270.
107. Rafter J. Bennett M. Caderni G. et al. Dietary synbiotics reduce cancer risk factors in polypectomized and colon cancer patients. AmJ Clin Nutr 2007 85:488-496.
108. Pala V. Sieri S. Berrino F. et al. Yogurt consumption and risk of colorectal cancer in the Italian European prospective investigation into cancer and nutrition cohort. Int J Cancer 2011 129:2712-2719.
109. Redman M.G. Ward E.J. Phillips R.S. The efficacy and safety of probiotics in people with cancer: a systematic review. Ann Oncol 2014 25:1919-1929.
110. Alverdy J.C. Laughlin R.S. Wu L. Influence of the critically ill state on host-pathogen interactions within the intestine: gut-derived sepsis redefined. Crit Care Med 2003 31:598-607.
111. Meakins J.L. Marshall J.C. The gastrointestinal tract: the "motor" of MOF. Arch Surg 1986 121:197-201.
112. Morrow L.E. Koffef M.H. Casale T.B. Probiotic prophylaxis of ventilator-associated pneumonia. A blinded randomized controlled trial. Am J Resp Crit Care Med 2010 182:1058-1064.
113. Spindler-Vesel A. Bengmark S. Vovk I. et al. Synbiotics prebiotics glutamine or peptide in early enteral nutrition: a randomized study in trauma patients. JPEN J Parenter Enteral Nutr 2007 31:119-126.
114. Kotzampassi K. Giamarellos-Bourboulis E.J. Voudouris A. et al. Benefits of a synbiotic formula (Synbiotic 2000Forte) in critically ill trauma patients: early results of a randomized controlled trial. World J Surg 2006 30:1848-1855.
115. Siempos Ntaidou T.K. Falagas M.E. Impact of the administration of probiotics on the incidence of ventilator-associated pneumonia: a meta-analysis of randomized controlled trials. Crit Care Med 2010 38:954-962.
116. Gu W.J. Wei C.Y. Yin R.X. Lack of efficacy of probiotics in preventing ventilator-associated pneumonia. A systematic review and meta-analysis of randomized controlled trials. Chest 2012 142:859-868.
117. Gu W.J. Deng T. Gong Y.Z. et al. The effect of probiotics in early enteral nutrition on the outcomes of trauma: a meta-analysis of randomized controlled trials. JPEN J Parenter Enteral Nutr 2013 37:310-317.
118. Petrof E.O. Dhaliwal R. Manzanares W. et al. Probiotics in the critically ill: a systematic review of the randomized trial evidence. Crit Care Med 2012 40:3290-3302.
119. Jeppsson B. Mangell P. Thorlacius. Use of probiotics as prophylaxis for postoperative infections. Nutrients 2011 3:604-612.
120. Dhaliwal R. Cahill N. Lemieux M. et al. The Canadian critical care nutrition guidelines in 2013: an update on current recommendations and implementation strategies. Nutr Clin Pract 2014 29:29-43.
121. McClave S.A. Martindale R.G. Vanek V.W. et al. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient. JPEN J Parent Enteral Nutr 2009 33:277-316.
122. Henao-Mejia J. Elinav E. Jin C. et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012 482:179-185.
123. Loguercio C. Federico A. Tuccillo C. et al. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol 2005 39:540-543.
124. Eslamparast T. Poustchi H. Zamani F. et al. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized double-blind placebo-controlled pilot study. Am J Clin Nutr 2014 99:535-542.
125. Vajro P. Mandato C. Licenziati M.R. et al. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr 2011 52:740-743.
126. Aller R. De Luis D.A. Izaola O. et al. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci 2011 15:1090-1095.
127. Malaguarnera M. Vacante M. Antic T. et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci 2012 57:545-553.
128. Ma Y.Y. Li L. Yu C.H. et al. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol 2013 19:6911-6918.
129. Chalasani N. Younossi Z. Lavine J.E. et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases American College of Gastroenterology and the American Gastroenterological Association. Am J Gastroenterol 2012 107:811-826.
130. Nam Y.D. Kim H.J. Seo J.G. et al. Impact of pelvic radiotherapy on gut microbiota of gynecological cancer patients revealed by massive pyrosequencing. PLOS One 2013 8:e82659.
131. Demers M. Dagnault A. Desjardins J. A randomized double-blind controlled trial: impact of probiotics on diarrhea in patients treated with pelvic radiation. Clin Nutr 2014 33:761-767.
132. Urbancsek H. Kazar T. Mezes I. et al. Results of a double-blind randomized study to evaluate the efficacy and safety of Antibiophilus in patients with radiation-induced diarrhoea. Eur J Gastroenterol Hepatol 2001 13:391-396.
133. Giralt J. Regadera J.P. Verges R. et al. Effects of probiotic Lactobacillus casei DN-114 001 in prevention of radiation-induced diarrhea: results from multicenter randomized placebo-controlled nutritional trial. Int J Radiat Oncol Biol Phys 2008 71:1213-1219.
134. Wedlake L.J. Shaw C. Whelan K. et al. Aliment Pharmacol Ther 2013 37:1046-1056.
135. Gibson R.J. Keefe D.M. Lalia R.V. Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. Support Care Cancer 2013 21:313-326.
136. Hamad A. Fragkos K.C. Forbes A. A systematic review and meta-analysis of probiotics for the management of radiation induced bowel disease. Clin Nutr 2013 32:353-360.
137. Sanders M.E. Akkermans L.M.A. Haller D. et al. Safety assessment of probiotics for human use. Gut Microbes 2010 1:164-185.
138. Besselink M.G. van Santvoort H.C. Buskens E. et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised double-blind placebo-controlled trial. Lancet 2008 371:651-659.
139. Del Piano M. Carmagnola S. Ballare M. et al. Is microencapsulation the future of probiotic preparations? The increased efficacy of gastro-protected probiotics. Gut Microbes 2011 2:120-123.
140. Cartman S.T. Time to consider Clostridium probiotics?. Future Microbiol 2011 6:969-971.
141. Shimbo I. Yamaguchi T. Odaka T. et al. Effect of Clostridium butyricum on fecal flora in Helicobacter pylori eradication therapy. World J Gastroenterol 2005 11:7520-7524.
142. Takahashi M. Taguchi H. Yamaguchi H. et al. The effect of probiotic treatment with Clostridium butyricum on enterohemorrhagic Escherechia coli 0157:H7 infection in mice. FEMS Immunol Med Microbiol 2004 41:219-226.
143. Woo T.D. Oka K. Takahashi M. et al. Inhibition of the cytotoxic effect of Clostridium difficile in vitro by Clostridium butyricum MIYAIRI 588 strain. J Med Microbiol 2011 60:1617-1625.
144. Motta J.P. Bermudez-Humaran L.G. Deraison C. et al. Food-grade bacteria expressing elafin protect against inflammation and restore colon homeostasis. Sci Transl Med 2012 31:158ra144.
145. Han W. Mercenier A. Ait-Belgnaoui A. et al. Improvement of an experimental colitis in rats by lactic acid bacteria producing superoxide dismutase. Inlamm Bowel Dis 2006 12:1044-1052.
146. Bermudez-Humaran L.G. Aubry C. Motta J.P. et al. Engineering lactococci and lactobacilli for human health. Curr Opin Microbiol 2013 16:278-283.
147. Chen Z. Guo L. Zhang Y. et al. Incorporation of therapeutically modified bacteria into gut microbiota inhibits obesity. J Clin Invest 2014 124:3391-3406.